0001209191-20-059156.txt : 20201118 0001209191-20-059156.hdr.sgml : 20201118 20201118165834 ACCESSION NUMBER: 0001209191-20-059156 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201116 FILED AS OF DATE: 20201118 DATE AS OF CHANGE: 20201118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SWAIN PAULA J CENTRAL INDEX KEY: 0001236934 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 201325763 MAIL ADDRESS: STREET 1: C/O INCYTE CORPORATION STREET 2: 3160 PORTER DRIVE CITY: PALO LATO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-16 0 0000879169 INCYTE CORP INCY 0001236934 SWAIN PAULA J 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP, Human Resources Common Stock 2020-11-16 4 A 0 1232 0.00 A 54013 D Represents shares of common stock underlying performance shares earned upon the interim achievement of performance criteria determined to be satisfied on November 16, 2020. The earned shares will vest on the third anniversary of the July 2, 2020 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 175% of the number of performance shares awarded. Including the Performance Stock Units earned on November 16, 2020, this includes an aggregate of 21,700 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. /s/ Paula Swain 2020-11-18